Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

/in

STORM recognised as an innovative early-stage biotechnology company pioneering novel drug targets 12 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes for oncology and other diseases, is pleased to announce that Fierce Biotech has named it as one of its 2022 “Fierce 15”, designating […]

Read more

Sequana Medical announces H1 2022 results and provides business update

/in

alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON study in Q4 2022 DSR® – clinical evidence of disease-modifying heart failure drug therapy / preparations ongoing to start US phase 1b/2a MOJAVE study in H1 2023 Total liquidity position of €23.8 million and cash runway into Q3 […]

Read more

Professor Melief to receive 2022 SITC Pedro J. Romero Award

/in

The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy field Second SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro […]

Read more

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

/in

7 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director. Read more…

Read more

BII announces new cohort of companies entering the Venture Lab program

/in

BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class life science research, today announces the latest cohort of participants in its Venture Lab acceleration program for early-stage companies. The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – all strategically aligned with BII’s focus on developing ground-breaking scientific initiatives […]

Read more